Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fib ...

New research confirms that gut microbes from fibromyalgia patients trigger chronic pain, immune activation, and nerve changes ...

The following is a summary of “Evaluation of clinical impact of Interleukin 8 gene expression in patients with fibromyalgia,” published in the April 2025 issue of Advances in Rheumatology by Amorim et ...

Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE ...

Silo Pharma, Inc. (NASDAQ:SILO) on Wednesday released results for its preclinical study evaluating SP-26. SP-26 is a ketamine ...

Medical cannabis has gained significant attention in recent years as a potential treatment for various health conditions, particularly chronic pain. As more research emerges, it’s becoming clearer ...

Fibromyalgia can be a debilitating illness due to its persistent fatigue and muscle aches. It can seriously and negatively ...